The US Pharmacopeia (USP) has developed the first official monographs on somatropin, or human growth hormone (HGH)1. HGH is used to treat children of pathologically short stature, but the healthcare community is continuing to find new uses and applications for it. The monographs were issued in the First Supplement of the United States Pharmacopeia 28 and National Formulary 23 (USP 28 - NF 23) and became official on 1 April 2005.
According to the Generic Pharmaceutical Association (GPhA), despite the brand industry's arguments that biopharmaceuticals cannot be adequately characterised, the ‘new...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?